You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Budget Impact Analysis of Introducing the Elecsys® PRO-C3 assay as part of the ADAPT Algorithm for Assessing the Severity of Hepatic Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the UK
This budget impact analysis projected that implementing the ADAPT algorithm (using age, diabetes, PRO-C3, and platelet count) for MASLD fibrosis assessment in the UK would yield £91 million in total savings over five years, driven primarily by the high testing specificity of the new tool.
Request medical material
Would you like to receive this poster via email to view later?